Abintus Bio leads the field of in vivo immune cell reprogramming. We pursue products that modulate immune cells from within their native environment to enhance patient access and patient outcomes.
years of collective experience and know-how
Abintus Bio, Inc. is a San Diego-based, preclinical stage gene therapy company focused on the discovery and development of a portfolio of first-in-class, product candidates that are designed to directly reprogram immune cells from within their native environment using proprietary vectors and related technologies.
Abintus is leveraging over $275 million of prior investment in the advancement of in vivo retroviral technology and has over 87 years of collective experience and know-how with the engineering, manufacturing and development of in vivo retroviral vectors, including the treatment of over 350 patients through Phase 3 registration trials and late-stage commercial launch planning.
27+ years viral and cell therapy manufacturing science and technology
Multiple issued manufacturing related patents
Seasoned leader of CMC operations at several gene and cell therapy companies from start-up through GMP PPQ validations
20+ years immunology/virus research and development
10+ years leading clinical biomarker, assay development and MOA studies in cancer gene therapy
Inventor and patent holder in the fields of cancer and gene therapy
15+ years translational science focused in oncology and immuno-oncology
Product-oriented biotech entrepreneur and founder with a focus on scientific strategy to achieve critical milestones and drive value
30+ years biotech drug development, primarily in gene therapy
125+ publications and 50+ US, Europe and Asia patents
Retroviral vector pioneer since 1983, ex-board member ASGCT
Co-founder of 4 gene therapy companies (Viagene, Advantagene, Tocagen, Abintus)
13+ years operational experience building biotech value
$1B+ from licensing, grants, private and public equities
“Only Financial Officer”
Serial finance executive specializing in biotech start-ups
Consultant at Abintus Bio, Inc.
At Abintus, we are passionate about scientific excellence and the patients that we serve. Our name comes from the Latin words “ab intus”, which means “from within”. The founding team chose the name for three reasons:
We are driven and inspired by our vision: Empowering Patients From Within. We are pursuing products that are designed to directly empower patients’ own immune cells to fight their disease.
Our world-class team is committed to scientific excellence. Our cutting-edge technologies have the potential to directly transform activated immune cells in situ, or from within.
Our ability to achieve our vision relies on each and every employee to contribute from within to build and shape our performance-driven culture.
We currently do not have any open positions but please contact us if you would like to join our world-class team and become part of our story.
For Recruiters/Agencies: Abintus does not accept unsolicited referrals or resumes from any source other than directly from candidates. We will not consider unsolicited referrals and/or resumes from vendors including and without limitation, search firms, staffing agencies, fee-based referral services and recruiting agencies. The submission of referrals or resumes by anyone other than a candidate directly to Abintus employees is strictly prohibited. Unsolicited referrals and resumes sent to Abintus are deemed gratuitous, and the company will not be obligated or bound in any way to pay any referral or other fee if a person referred to us from a source other than a candidate is hired.
Notwithstanding the foregoing, resumes will be accepted from approved vendors who have written agreements in place with Abintus, and then only to the extent such agreement covers a specified position and, if required by such agreement, the submission of resumes by the vendor has been authorized in writing by Abintus for such specified position. Any resume submitted in the absence of a signed agreement will become the property of Abintus and no fee shall be due.